Subjects: Antibodies, Monoclonal, Humanized -- adverse effects and Diphosphonates -- adverse effects / Publication Year: 2017 - Digital Collections - National Library of Medicine Search Results

Start Over Subjects Antibodies, Monoclonal, Humanized -- adverse effects ✖ Subjects Diphosphonates -- adverse effects ✖ Publication Year 2017 ✖

1. Anabolic therapies for osteoporosis in postmenopausal women: effectiveness and value : final evidence report

Publication:: [Boston, Massachusetts] : Institute for Clinical and Economic Review, July 17, 2017
Subject(s):: Anabolic Agents -- therapeutic use
Antibodies, Monoclonal, Humanized -- therapeutic use
Osteoporosis, Postmenopausal -- drug therapy
Parathyroid Hormone-Related Protein -- therapeutic use
Anabolic Agents -- adverse effects
Anabolic Agents -- economics
Antibodies, Monoclonal, Humanized -- adverse effects
Antibodies, Monoclonal, Humanized -- economics
Bone Density Conservation Agents -- adverse effects
Bone Density Conservation Agents -- economics
Bone Density Conservation Agents -- therapeutic use
Comparative Effectiveness Research
Diphosphonates -- adverse effects
Diphosphonates -- economics
Diphosphonates -- therapeutic use
Osteoporotic Fractures -- prevention & control
Parathyroid Hormone-Related Protein -- adverse effects
Parathyroid Hormone-Related Protein -- economics
Randomized Controlled Trials as Topic
Teriparatide -- adverse effects
Teriparatide -- economics
Teriparatide -- therapeutic use
Humans
United States